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Abstract
Purpose To evaluate the effects of myometrial thickening
on the outcomes of in vitro fertilization and embryo transfer
(IVF-ET).
Methods Four hundred thirteen patients, a total of 551 IVF-
ET cycles, were divided into group A (<2.00 cm), group B
(2.00–2.49 cm), and group C (≥2.50 cm) based on
myometrial thickness.
Results The implantation, clinical pregnancy, and live birth
rates were significantly lower in group C. The abortion rates
were significantly higher in group C. Among patients in group
B, cases with other sonographic findings suggestive of
adenomyosis, such as myometrial striations, heterogeneous
myometrium, myometrial cysts, and poor definition of the
endometrial–myometrial junction showed lower implantation,
clinical pregnancy, live birth rates, and higher abortion rates.
Conclusions Myometrial thickening of more than 2.50 cm
on TVUS exerts overall adverse effects on IVF-ET out-
comes. Even with mild thickening (2.00–2.49 cm), the
presence of sonographic findings suggestive of adenomyo-
sis is associated with adverse outcomes of IVF-ET.
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Introduction
A baseline imaging study of the uterus, endometrium,
ovary, and fallopian tube by transvaginal ultrasonography
(TVUS) is an important step for predicting pregnancy
outcomes in infertile patients undergoing in vitro fertiliza-
tion and embryo transfer (IVF-ET). A diffusely enlarged
uterus, in the absence of a well circumscribed mass as in
uterine myomas, can be considered as adenomyosis, the
influence of hormones, and secondary enlargement due to
vascular lesions [1]. Among these, adenomyosis is gener-
ally the first consideration. Such findings are frequently
observed in patients undergoing IVF-ET. Therefore, the
impact of such findings on the outcomes of IVF-ET must
be considered when counseling patients.
Adenomyosis is caused by invasion of the endometrial
gland and stroma into the myometrium, and is associated
with myometrial hypertrophy and hyperplasia [2, 3].
Definite histopathologic diagnosis of adenomyosis through
hysterectomy is not possible in patients who want to
conceive. Therefore, an alternative diagnostic method is
correlation of clinical symptoms and imaging modalities,
such as TVUS, computed tomography (CT), and magnetic
resonance imaging (MRI).
Although there is no current consensus for diagnostic
criteria of adenomyosis based on imaging studies, diagnos-
tic criteria for adenomyosis through TVUS can be based on
characteristic findings of two components. One is the
‘myosis’-component, which includes myometrial thicken-
ing with globular uterine configuration and/or myometrial
anteroposterior asymmetry, and myometrial striations. The
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other is the presence of ectopic endometrial implants, the
‘adeno’-component, which includes heterogeneous myome-
trium, myometrial cysts, and poor definition of the
endometrial–myometrial junction. These findings other
than myometrial thickening still require definitive histo-
pathologic confirmation. The evaluation of such findings is
very subjective and may differ greatly depending on the
examiner [4–11].
In the current study, the degree of uterine enlargement
was classified according to myometrial thickness on TVUS
to evaluate effects of myometrial thickening on IVF-ET
outcomes. Additionally, other sonographic findings sugges-
tive of adenomyosis were examined and analyzed its effects
on IVF-ET outcomes.
Materials and methods
This investigation was designed as retrospective case-
controlled analysis. From January 2000 to December
2009, 413 patients (551 cycles) out of 763 patients (1067
cycles) undergoing IVF-ET at our infertility clinic were
included. The study group excluded cases aged older than
40 years, cases demonstrating a well circumscribed mass
suggestive of a uterine myoma by TVUS, cases in which
male factor is the cause of infertility, and cases demonstrat-
ing poor response to controlled ovarian hyperstimulation
(COH).
All patients received TVUS examination prior to
induction of COH, during COH, and on the day of
triggering of ovulation for evaluation of follicles,
endometrium and myometrium with the Aloka SSD-
5000 or the Aloka SSD-α10 device. Myometrial thick-
ness was measured retrospectively from longitudinal
view image of the uterus taken on the day of triggering
of ovulation with human chorionic gonadotrophin (hCG).
Myometrial thickness of the anterior, posterior, and
fundal myometrium was measured using the borderline
of endometrium and uterine serosa as end points. The
largest of the three values was defined as the maximum
myometrial thickness.
Infertility work-up, COH, oocyte retrieval, embryo
transfer (ET) and TVUS examination of all patients
included in our study was performed at our infertility clinic
by a single infertility specialist. The TVUS images and
records were reviewed and reevaluated with another
specialist.
Patients were divided into three groups according to
maximum myometrial thickness: group A (<2.00 cm: 302
patients, 397 cycles), group B (2.00–2.49 cm: 63 patients,
81 cycles), and group C (≥2.50 cm: 48 patients, 73 cycles).
The sonographic findings suggestive of adenomyosis such
as myometrial striations, heterogeneous myometrium, myo-
metrial cysts, and poor definition of the endometrial-
myometrial junction, were examined.
Gonadotropin-releasing hormone agonist (GnRH-a,
Superfact, Sanofi-Aventis, Paris, France) and recombinant
human follicle stimulating hormone (rhFSH, Gonal F,
Merck Serno, Geneva, Switzerland) were used for COH.
hCG (Pregnyl, Schering-Plough, Kenilworth, NJ, USA)
10,000 IU was injected intramuscularly or recombinant
hCG (rhCG, Ovidrel, Merck Serno, Geneva, Switzerland)
250 μg was injected subcutaneously when one or more
follicles reached a mean diameter of 18 mm. Thirty-five
hours after injection of hCG, the oocyte-cumulus complex
was retrieved by ultrasonography-guided aspiration and
fertilization was performed 4–6 h after retrieval. The
fertilized embryos were transferred 3 days after oocyte
retrieval. The luteal phase was supported with progesterone
in oil 50–100 mg daily, initially for 14 days starting on the
day of oocyte retrieval and continued for another 2–4 weeks
in cases where a pregnancy was achieved. A clinical
pregnancy was defined by the presence of an intrauterine
gestational sac with pulsating fetal heart beats 3–4 weeks
after oocyte retrieval [12].
The power of the study was calculated through a PS
sample size calculator. With the level of significance put at
0.05, the power can be calculated as 52.7%. Statistical
analysis was performed using the SPSS version 18.0 (SPSS
Inc., Chicago, IL, USA). The results were compared among
three groups and statistically analyzed using chi-square test
and ANOVA. Differences were considered statistically
significant at P<0.05.
This study was approved by Institutional Ethics Com-
mittee of Yonsei University Wonju College of Medicine.
Results
For all 413 patients, the myometrial thickness (mean ± SD)
for each area was as follows: anterior, 1.66±0.48 cm;
posterior, 1.70±0.50 cm; fundal, 1.37±0.35 cm. There were
significant differences in myometrial thickness according to
area. The posterior myometrium was thickest (P<0.05). In
group A (302 patients), myometrial thickness at each area
was as follows: anterior, 1.51±0.21 cm; posterior, 1.56±
0.21 cm; fundal, 1.30±0.19 cm. Myometrial thickness was
statistically significantly different between areas; the poste-
rior myometrium was thickest (P<0.05). In group A, B-1
and C-1 (353 patients; cases without other sonographic
findings suggestive of adenomyosis), myometrial thick-
ness at each area was as follows: anterior, 1.58±0.27 cm;
posterior, 1.63±0.27 cm; fundal, 1.32±0.21 cm. Myo-
metrial thickness was statistically significantly different
between areas; the posterior myometrium was thickest
(P<0.05).
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Clinical characteristics including patient age, duration of
infertility, number of previous IVF-ET cycles, and causes of
infertility were not different among the three groups
(Table 1). Serum E2 levels on day of hCG administration,
number of oocytes retrieved, number of fertilized oocytes,
fertilization rates, and number of embryos transferred were
not different among the three groups. The endometrial
thickness on the day of hCG administration for group C
was significantly thinner than that of group A and B (P<0.05).
The implantation, clinical pregnancy, and live birth rates of
group C (12.3%, 31.5%, 15.1%, respectively) were signifi-
cantly lower than those of group A (22.8%, 56.4%, 46.9%,
respectively) and B (21.9%, 53.1%, 40.7%, respectively).
The abortion rates of group C (52.2%) were significantly
higher than those of group A (12.9%) and B (20.9%). The
ectopic pregnancy rates were not significantly different
among three groups (Table 2).
Cases with other sonographic findings suggestive of
adenomyosis, such as myometrial striation, heterogeneous
myometrium, myometrial cysts, and poor definition of the
endometrial–myometrial junction were 29 cycles (35.8%)
in group B and 52 cycles (71.2%) in group C. In group B,
cases with other sonographic findings suggestive of
adenomyosis showed significantly lower implantation,
clinical pregnancy, and live birth rates and higher abortion
rates compared to cases without these findings (12.4%,
34.5%, 17.2%, 50.0% vs. 27.2%, 63.5%, 53.8%, 12.1%,
respectively; P<0.05). In group C, there were no significant
differences in implantation, clinical pregnancy, live birth,
and abortion rates between cases with or without these
findings (11.6%, 26.9%, 11.5%, 57.1% vs. 14.0%, 42.9%,
23.8%, 44.4%, respectively) (Table 3).
Discussion
Mean myometrial thickness varies in literature. In ‘Berek &
Novak’s gynecology’, myometrial thickness ranges from
1.50 to 2.50 cm [13]. Although there is no study on the
precise measurement of mean myometrial thickness in
reproductive age women by TVUS, according to ‘Ultraso-
nography in obstetrics and gynecology’, the anteriorposte-
rior (AP) diameter is 2.00–5.00 cm in reproductive women
(2.00–4.00 cm in nulliparas, 3.00–5.00 cm in multiparas)
[14]. From which normal range of myometrial thickness is
estimated to be roughly 1.00–2.50 cm. Diffuse uterine
myohypertrophy (DUMH) is a condition clinically diag-
nosed by the presence of uterine bleeding, homogeneous
and diffuse uterine enlargement, and absence of any
myoendometrial cause of bleeding. One of the diagnostic
criteria of DUMH is myometrial thickness of at least
2.00 cm [15]. In our study, mean myometrial thickness of
patients without other sonographic findings suggestive of
adenomyosis (group A, B-1 and C-1; 353 patients) was as
follows: anterior, 1.58±0.27 cm; posterior, 1.63±0.27 cm;
fundal, 1.32±0.21 cm. About 75% (73%; 302 patients) of
all patients (413 patients) had myometrial thickness of less
than 2.00 cm, and about 90% (88%; 365 patients) had
myometrial thickness less than 2.50 cm. Based on these
findings, the authors considered thickened myometrium as
2.50 cm or more, mild thickness or upper normal as 2.00–
2.49 cm, and normal thickness as less than 2.00 cm.
The outcomes of IVF-ET according to myometrial
thickness were compared. Significant reductions in implan-
tation, clinical pregnancy, and live birth rates and increases
in the abortion rates were observed in group C. Group
B demonstrated mild myometrial thickening and, in
comparison to group A, a reduction in implantation, clinical
pregnancy, and live birth rates and an increase in the
abortion rate were observed, though these were not
significant.
The current study demonstrates that as myometrial
thickness increases, it exerts overall adverse effects on
IVF-ET outcomes. This differs from a study by Camargo et
al., which found no effects of adenomyosis on IVF-ET
outcomes [16]. However, they did not consider myometrial
thickening but used the presence of myometrial cysts as a
diagnostic criteria for adenomyosis, which may be attribut-
Table 1 Clinical data of
patients
NS not significant.









Age (years)a 33.0±3.7 33.7±3.7 33.6±3.7 NS
Duration of infertility
(years)a
3.2±1.2 3.3±1.4 3.3±1.5 NS
No. of previous IVF-ET
cyclesa
0.5±0.7 0.5±0.8 0.5±0.7 NS
No. of causes of infertility
Tubal factor (%) 160 (40.3) 32 (39.5) 26 (35.6) NS
Endometriosis (%) 39 (9.8) 7 (8.6) 11 (15.1) NS
Anovulatory (%) 55 (13.9) 10 (12.3) 9 (12.3) NS
Unexplained (%) 143 (36.0) 32 (39.5) 27 (37.0) NS
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ed to the conflicting results. The results of the current study
are also different from a study by Chiang et al. They
evaluated IVF-ET outcomes in 19 infertile patients with a
sonographical pattern of diffusely enlarged uterus without
distinct uterine masses defined by the criteria such as the
presence of a diffusely enlarged uterus and one or more
heterogeneous myometrial areas not encapsulated and
within round anechoic areas 1–3 mm in diameter and
reported that pregnancy outcomes, excluding abortion rates,
were not different from age-controlled group of 144
Table 2 Response to ovarian stimulation and clinical outcomes
Group A (397 cycles) Group B (81 cycles) Group C (73 cycles) P-value
E2 level, hCG day (pg/mL)
a 1930.2±1319.1 1725.3±1314.0 2017.0±1306.7 NS
Endometrial thickness, hCG day (cm)a 1.1±0.2 1.1±0.2 0.9±0.2b 0.001
No. of oocytes retrieveda 11.4±7.2 11.8±8.2 10.2±5.0 NS
No. of fertilized oocytesa 8.2±5.6 8.3±6.4 7.5±3.9 NS
Fertilization rate per retrieved oocyte (%)a 82.2±18.7 81.7±17.0 82.1±19.6 NS
No. of embryos transferreda 3.1±0.8 3.2±0.8 3.1±0.8 NS
Implantation rate (%) 264/1158 (22.8) 55/251 (21.9) 28/228 (12.3)b 0.002
2000–2004 (290 cycles) 133/627 (21.2) 25/123 (20.3) 11/102 (10.8)b 0.04
2005–2009 (261 cycles) 131/531 (24.7) 30/128 (23.4) 17/126 (13.5)b 0.03
Clinical pregnancy/cycle (%) 224/397 (56.4) 43/81 (53.1) 23/73 (31.5)b 0.02
2000–2004 (290 cycles) 122/219 (55.7) 24/43 (55.8) 8/28 (28.6)b 0.02
2005–2009 (261 cycles) 102/178 (57.3) 19/38 (50.0) 15/45 (33.3)b 0.02
Abortion/clinical pregnancy (%) 29/224 (12.9) 9/43 (20.9) 12/23 (52.2)b <0.001
2000–2004 (290 cycles) 16/122 (13.1) 5/24 (20.8) 5/10 (50.0)b 0.009
2005–2009 (261 cycles) 13/102 (12.7) 4/19 (21.1) 7/13 (53.8)b 0.001
Ectopic pregnancy/clinical pregnancy (%) 9/224 (4.0) 1/43 (2.3) 0/23 (0.0) NS
2000–2004 (290 cycles) 5/122 (4.1) 1/24 (4.2) 0/10 (0.0) NS
2005–2009 (261 cycles) 4/102 (3.9) 0/19 (0.0) 0/13 (0.0) NS
Live birth/cycle (%) 186/397 (46.9) 33/81 (40.7) 11/73 (15.1)b <0.001
2000–2004 (290 cycles) 101/219 (46.1) 18/43 (41.9) 5/28 (17.9)b 0.017
2005–2009 (261 cycles) 85/178 (47.8) 15/38 (39.5) 6/45 (13.3)b <0.001
NS not significant.
a Data are mean ± SD.
b Significantly different to corresponding values in group A and B (P<0.05).
Table 3 Clinical outcomes in cases with and without sonographic findings suggestive of adenomyosis in group B and C
Group B (81 cycles) P-value Group C (73 cycles) P-value
B-1 (52 cycles) B-2 (29 cycles) C-1 (21 cycles) C-2 (52 cycles)
Implantation rate (%) 44/162 (27.2) 11/89 (12.4)a 0.007 9/64 (14.0) 19/164 (11.6) NS
Clinical pregnancy/cycle (%) 33/52 (63.5) 10/29 (34.5)a 0.012 9/21 (42.9) 14/52 (26.9) NS
Abortion/clinical pregnancy (%) 4/33 (12.1) 5/10 (50.0)a 0.01 4/9 (44.4) 8/14 (57.1) NS
Live birth/cycle (%) 28/52 (53.8) 5/29 (17.2)a 0.001 5/21 (23.8) 6/52 (11.5) NS
B-1: Group B without myometrial striation, heterogeneous myometrium, myometrial cysts, or poor definition of the endometrial–myometrial
junction
B-2: Group B with myometrial striation, heterogeneous myometrium, myometrial cysts, or poor definition of the endometrial–myometrial junction
C-1: Group C without myometrial striation, heterogeneous myometrium, myometrial cysts, or poor definition of the endometrial–myometrial
junction
C-2: Group C with myometrial striation, heterogeneous myometrium, myometrial cysts, or poor definition of the endometrial–myometrial junction
NS not significant.
a Significantly different to corresponding values in group B-1 (P<0.05).
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infertile patients [17]. This is thought to be secondary to the
fact that this study did not classify the degree of myometrial
thickening.
In group C, cases with myometrial thickness exceeding
2.50 cm in the anterior, posterior, and fundal myometrium
were 37.5%, 64.6%, and 14.6% of the total, respectively.
The most frequently observed area where the myometrial
thickness was greater than 2.50 cm was the posterior
myometrium. Forty-one patients (85.4%) had a myometrial
thickness exceeding 2.50 cm in one area. Seven patients
(14.6%) had a myometrial thickness exceeding 2.50 cm in
more than two areas. Clinical pregnancy was achieved in
cases with a myometrial thickness exceeding 2.50 cm in
only one area (36.5%). In cases with thickening in more
than two areas of the myometrium, pregnancy could not be
achieved (data not shown).
Cases with other sonographic findings suggestive of
adenomyosis, such as myometrial striations, heteroge-
neous myometrium, myometrial cysts, and poor defini-
tion of the endometrial–myometrial junction, occurred in
35.8% of group B and 71.2% of group C. It was
observed that as the myometrium becomes thicker, it was
more likely that additional imaging findings were
present. In group B, significant differences in the clinical
outcomes between the patients with additional sono-
graphic findings and those without were observed. This
demonstrates that even with mild myometrial thicken-
ing, if other imaging findings characteristic of adeno-
myosis are associated, these may exert adverse effects
on IVF-ET outcomes.
The causes of adverse effects of adenomyosis on
pregnancy outcomes may include mechanical traction
and distortion of the myometrium, uterotubal spasm due
to prostaglandin released by ectopic endometrial
implants, and immunological factors [18–21]. The cur-
rent study found that endometrial thickness on the day of
hCG administration in group C was significantly thinner
than in group A and B. This suggests that the endometrium
may exert effects on pregnancy rates. It may be speculated
that the reduction in endometrial thickness is due to a
reduction of endometrial and subendometrial blood flow
[22–24].
In the current study, myometrial thickness was measured
by TVUS and divided by degree and the outcomes of IVF-
ET were compared in relation to the degree of myometrial
thickness. As a result, the authors found that myometrial
thickening exerts overall adverse effects on IVF-ET out-
comes. To our knowledge there have been no previous
studies on this subject. A limitation to our study is that
patients undergoing multiple IVF-ET cycles were also
included in the analysis. Although this may have no effect
on the study outcome because number of previous IVF-ET
cycles is very similar among group A, B and C (0.5±0.7,
0.5±0.8, 0.5±0.7, respectively), a large prospective studies
of only one cycle per patient are needed for a more accurate
analysis.
In conclusion, it was observed that myometrial thickening,
particularly myometrial thickening of more than 2.50 cm,
exerts overall adverse effects on IVF-EToutcomes. Even with
mild myometrial thickening (2.00–2.49 cm), in light of the
fact that adenomyosis is a progressive disease, immediate and
appropriate treatment plans are recommended.
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